$2.28
+0.07 (+3.17%)
Open$2.21
Previous Close$2.21
Day High$2.35
Day Low$1.95
52W High$5.55
52W Low$0.97
Volume—
Avg Volume850.9K
Market Cap138.86M
P/E Ratio—
EPS$-0.93
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,886.4% upside
Current
$2.28
$2.28
Target
$45.29
$45.29
$33.37
$45.29 avg
$67.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.30M | 59.72M | 61.79M |
| Net Income | -64,933,403 | -17,457,928 | -16,293,891 |
| Profit Margin | -574.6% | -29.2% | -26.4% |
| EBITDA | -62,617,430 | -19,228,267 | -21,164,861 |
| Free Cash Flow | — | -18,637,383 | -17,592,445 |
| Rev Growth | — | -4.4% | +5.4% |
| Debt/Equity | 0.00 | 0.30 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |